---
schema_version: "secwatch.filing_event.v1"
accession: "0001214659-24-017549"
form_type: "8-K"
ticker: "ALZN"
cik: "0001677077"
company_name: "Alzamend Neuro, Inc."
filed_at: "2024-10-15T23:59:59+00:00"
generated_at: "2026-05-30T14:37:15.794100+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Alzamend Neuro regains Nasdaq compliance; avoids delisting

## Summary
- Received written notice from Nasdaq Hearings Panel on Oct 14, 2024 that it has regained compliance with minimum stockholders' equity rule ($2.5M required).
- Had been notified of delisting in March 2024, appealed to Panel, granted extension until Sept 23, 2024.
- Entered $25M Series A Convertible Preferred purchase agreement; $8M already funded, additional $2M due in 30 days, $1M monthly through Jan 2026.
- CEO Stephan Jackman states strategic plan executed; company intends to initiate five phase II AL001 trials in 2025 with Massachusetts General Hospital.

## SEC filing metadata
- accession: 0001214659-24-017549
- form_type: 8-K
- ticker: ALZN
- cik: 0001677077
- company_name: Alzamend Neuro, Inc.
- filed_at: 2024-10-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1677077/000121465924017549/0001214659-24-017549-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1677077/000121465924017549/o10142408k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001214659-24-017549
- JSON: https://secwatch.observer/filing/0001214659-24-017549.json
- Plain text: https://secwatch.observer/filing/0001214659-24-017549.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.